BIG PLANS: Johnson & Johnson says it's poised by 2017 to seek regulatory approval for a dozen new medicines and two dozen variations of existing ones.
BIG IMPACT: Two experimental medicines could transform current treatments. One is an antidepressant that appears to work in just a day, instead of taking weeks. The other is a powerful painkiller that's not addictive.
BIG REBOUND: J&J has recovered from a sales drop in 2009, fueled by the launch of 11 new products since then. Last year, those drugs brought in about one-sixth of J&J's $25.4 billion in total pharmaceutical sales.